Strategic Partners A/S
OZYMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.75M
Close$
$2.77
96.9% downside
Current Fair Value
96.9% downsideOvervalued by 96.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.75 Million |
|---|---|
| Enterprise Value | $3.68 Million |
| Earnings per Share | $-21 |
| Beta | 0.29 |
| Outstanding Shares | 41,712 |
Return
| Return on Equity | -10.23% |
|---|---|
| Return on Assets | -9.88% |
| Return on Invested Capital | -24.62% |
Valuation & Multiples
| P/E Ratio | 20.9 |
|---|---|
| PEG | -11.25 |
| Price to Sales | 10.0 |
| Price to Book Ratio | 0.19 |
| Enterprise Value to Revenue | -0.17 |
| Enterprise Value to EBIT | 0.01 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 15, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Orphazyme A/S
62 employees
CEO: Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cel...